Clinical Trials Logo
NCT number NCT03360942
Study type Observational
Source Dartmouth-Hitchcock Medical Center
Contact
Status Active, not recruiting
Phase N/A
Start date April 18, 2016
Completion date November 22, 2028

Clinical Trial Summary

The long term follow up of a pilot study in which the invesitagors proposed to test whether high frequency stimulation of the subcallosal cingulate (SCC) is a safe and efficacious antidepressant treatment in five TRD patients, to compare the effects of left-sided vs. right-sided stimulation, and to investigate potential mechanisms of action of this intervention. Importantly, this study will be used to assess the need for and assist in planning a larger, more definitive trial of SCC DBS for TRD.


Clinical Trial Description

The U.S. lifetime prevalence of major depressive disorder (MDD) is 17%. A number of treatments are available for depression including medications, psychotherapy and various somatic treatments. Unfortunately, up to two-thirds of patients remain symptomatic following first-line treatment and a third fail to achieve remission (defined as full resolution of depressive symptoms) after four established treatments; approximately 10%-20% of depressed patients may show virtually no improvement despite multiple, often aggressive treatments. Thus, a conservative estimate places the U.S. prevalence of treatment-resistant depression (TRD) at 1%-3%. TRD has a high risk of suicide, is a major cause of disability and is responsible for doubling of overall health care costs.

For patients with TRD there are limited evidence-based treatment options. Transcranial magnetic stimulation (TMS) may have efficacy for patients that have failed no more than one antidepressant medication 10-12, but response and remission rates are relatively low (under 30% and 20% respectively). Vagus nerve stimulation (VNS) may have efficacy in patients that have failed 4-6 antidepressant treatments but long-term response and remission rates are again low (about 20% and 10% respectively). Electroconvulsive therapy(ECT) can be effective in TRD patients with remission rates of 50%-60%. However, more than 70% of TRD patients will relapse within 6 months following a successful acute treatment course. For patients that have failed ECT, there are no evidence-based treatment options. Therefore, there is great need for novel treatment approaches for TRD.

Prior clinical trials have shown that SCC DBS has the potential to be a valuable treatment option for patients with TRD. Further developing this treatment will involve confirming its effectiveness and identifying ways to optimize its use. In this study the investigators intend to test the safety and efficacy of chronic SCC DBS as a treatment for TRD and compare the safety and efficacy of left-sided versus right-sided stimulation using a double-blind, randomized, cross-over design.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02935595 - Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients Phase 2
Enrolling by invitation NCT03134066 - Neurocognitive Features of Patients With Treatment-Resistant Depression N/A
Recruiting NCT01984710 - DBS for TRD Medtronic Activa PC+S N/A
Completed NCT01935115 - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Phase 4
Terminated NCT01687478 - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Phase 3
Recruiting NCT00531726 - Berlin Deep Brain Stimulation Depression Study Phase 3
Recruiting NCT03272698 - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression Phase 4
Recruiting NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Recruiting NCT02611206 - Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms N/A
Active, not recruiting NCT00565617 - Epidural Cortical Stimulation for Depression N/A
Recruiting NCT02046330 - Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression N/A
Recruiting NCT01677078 - Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression Phase 3
Completed NCT01246908 - Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression Phase 2
Completed NCT00789854 - Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients Phase 3
Withdrawn NCT00178854 - Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment Phase 4
Enrolling by invitation NCT03240692 - Accelerated Theta Burst Stimulation in Treatment-Resistant Depression N/A
Completed NCT02150577 - Implementation Trial of Evidence Based Practices for Mood Disorders N/A
Enrolling by invitation NCT03290963 - Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine Phase 2
Withdrawn NCT00646087 - Ketamine Frequency Treatment for Major Depressive Disorder Phase 4
Recruiting NCT03068715 - Accelerated Theta Burst in Treatment-Resistant Depression N/A